Algernon Pharmaceuticals changes name to Algernon Health

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) completed its name change to Algernon Health Inc., the Canadian healthcare company announced October 15. The company's common shares will begin trading under the new name on the CSE at market open on October 20, 2025.

The shares will trade under the new name with a new CUSIP number (01559C106) and ISIN (CA01559C1068), while the stock symbol remains unchanged. No action is required by shareholders regarding the name change.

The company said the name change reflects its focus on the Alzheimer's disease diagnostic market with plans to establish neuroimaging clinics across North America. The clinics will feature FDA-cleared brain-specific Positron Emission Tomography (PET) scanning systems to detect amyloid plaques in patients.

Algernon recently signed a definitive equipment order and financing agreement with Catalyst MedTech for four Oncovision CareMiBrain brain-specific PET scanner systems for four planned neuroimaging medical clinics. The deal represents a value of over CDN $4 million and includes an agreement to acquire six additional systems for future clinics.

"Our change in name is an important step in the execution of our new health care initiative to establish and operate dedicated neuroimaging clinics for the early-stage detection of Alzheimer's disease," said Christopher J. Moreau, CEO of Algernon Health.

Algernon remains the parent company of private subsidiary Algernon NeuroScience, which is advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The company also owns a 20% equity position in Seyltx, a private U.S.-based drug development company advancing chronic cough drug Ifenprodil.

You May Also Be Interested In

• Kevin Knight retires from Knight-Swift Transportation
• Dexcom to present diabetes study results and launch updated glucose app
• Park Dental Partners acquires Zumbro View Dental in Rochester